TY - JOUR
T1 - Difference in the duration of pediatric diabetic ketoacidosis
T2 - Comparison of new-onset to known type 1 diabetes
AU - Valero-Guzmán, Leonardo
AU - Vásquez-Hoyos, Pablo
AU - Camacho-Cruz, Jhon
AU - Maya-Hijuelos, Luis Carlos
AU - Martínez-Lozada, Susan
AU - Rubiano-Acevedo, Ana María
AU - Lara-Bernal, Marleny
AU - Diaz-Angarita, Tomas
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Objective: To compare the duration (hours until (Formula presented.) ≥ 15 mmol/L) of diabetic ketoacidosis (DKA) episodes that are the first manifestation of new type 1 diabetes (NT1D) and those that are a complication in patients with previously diagnosed type 1 diabetes (PT1D). Methods: A multicenter retrospective cohort study was designed. The duration of DKA was measured from the start of the treatment. The primary outcome was the comparison of the time needed in each group to reach (Formula presented.) ≥ 15 mmol/L. The secondary outcomes were the comparison of the time to reach pH ≥ 7.3 and length of hospital stay in each group. Data were analyzed with a bivariate analysis of the variables vs primary outcome. Then, a regression model was analyzed. Results There were 305 episodes included (NT1D: 115, PT1D: 190). DKA in the NT1D group lasted longer (NT1D 20 (16-19) vs PT1D 12 (8-16), hours, P <.01) with a significant difference in each level of DKA severity. This group also took longer to reach pH ≥ 7.3 (NT1D 16 (12-22) vs PT1D 9 (6-12), hours, P <.01) and had a longer hospital stay (NT1D 9 (6-12) vs PT1D 7 (4-10), hours, P <.01). Conclusion: The duration of DKA is longer in patients with NT1D regardless of characteristics like DKA severity, duration of symptoms, and type of treatments received.
AB - Objective: To compare the duration (hours until (Formula presented.) ≥ 15 mmol/L) of diabetic ketoacidosis (DKA) episodes that are the first manifestation of new type 1 diabetes (NT1D) and those that are a complication in patients with previously diagnosed type 1 diabetes (PT1D). Methods: A multicenter retrospective cohort study was designed. The duration of DKA was measured from the start of the treatment. The primary outcome was the comparison of the time needed in each group to reach (Formula presented.) ≥ 15 mmol/L. The secondary outcomes were the comparison of the time to reach pH ≥ 7.3 and length of hospital stay in each group. Data were analyzed with a bivariate analysis of the variables vs primary outcome. Then, a regression model was analyzed. Results There were 305 episodes included (NT1D: 115, PT1D: 190). DKA in the NT1D group lasted longer (NT1D 20 (16-19) vs PT1D 12 (8-16), hours, P <.01) with a significant difference in each level of DKA severity. This group also took longer to reach pH ≥ 7.3 (NT1D 16 (12-22) vs PT1D 9 (6-12), hours, P <.01) and had a longer hospital stay (NT1D 9 (6-12) vs PT1D 7 (4-10), hours, P <.01). Conclusion: The duration of DKA is longer in patients with NT1D regardless of characteristics like DKA severity, duration of symptoms, and type of treatments received.
UR - http://www.scopus.com/inward/record.url?scp=85082576922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082576922&partnerID=8YFLogxK
U2 - 10.1111/pedi.13007
DO - 10.1111/pedi.13007
M3 - Article
C2 - 32181961
AN - SCOPUS:85082576922
SN - 1399-543X
VL - 21
SP - 791
EP - 799
JO - Pediatric Diabetes
JF - Pediatric Diabetes
IS - 5
ER -
